2018
Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.
Verplaetse TL, McKee SA, Petrakis IL. Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems. Alcohol Research 2018, 39: 193-205. PMID: 31198658, PMCID: PMC6561397.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderCo-occurring alcohol use disorderAlcohol use disorderComorbid alcohol use disorderStress disorderNeurobiological systemsMaintenance of AUDUse disordersPTSD symptom severityAlcohol-motivated behaviorsAlcohol use outcomesPharmacologic treatment strategiesBrain systemsTreatment of individualsCurrent medicationsComorbid populationGlutamatergic systemPotential pharmacotherapyPharmacologic interventionsUse outcomesTreatment outcomesTreatment strategiesSingular diagnosisDual diagnosisTreatment interventions
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen